Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Laine-Cessac, P.; Cailleux, A.; Allain, P.
    Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs (1997), Biochem. Pharmacol., 54, 863-870.
    View publication on PubMed

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.7.1.35 cycloserine 0.1 mM, inhibits activity with pyridoxal, but not with pyridoxamine as substrate, 42% inhibition Homo sapiens
2.7.1.35 D-penicillamine 0.1 mM, inhibits activity with pyridoxal, but not with pyridoxamine as substrate, 20% inhibition Homo sapiens
2.7.1.35 dopamine 0.1 mM, inhibits activity with pyridoxal, but not with pyridoxamine as substrate, 52% inhibition Homo sapiens
2.7.1.35 isoniazid 0.1 mM, inhibits activity with pyridoxal, but not with pyridoxamine as substrate, 81% inhibition Homo sapiens
2.7.1.35 levodopa 0.1 mM, inhibits activity with pyridoxal, but not with pyridoxamine as substrate, 16% inhibition Homo sapiens
2.7.1.35 muzolimine 0.1 mM, inhibits activity with pyridoxal, but not with pyridoxamine as substrate, 27% inhibition Homo sapiens
2.7.1.35 progabide 0.1 mM, inhibits using either pyridoxamine or pyridoxal as substrate Homo sapiens
2.7.1.35 theophylline 0.1 mM, inhibits using either pyridoxamine or pyridoxal as substrate, 86% inhibition of reaction with pyridoxal, 88% inhibition of reaction with pyridoxamine Homo sapiens
2.7.1.35 Thiamphenicol 0.1 mM, inhibits activity with pyridoxal, but not with pyridoxamine as substrate, 31% inhibition Homo sapiens

Organism

EC Number Organism UniProt Comment Textmining
2.7.1.35 Homo sapiens
-
-
-

Source Tissue

EC Number Source Tissue Comment Organism Textmining
2.7.1.35 erythrocyte
-
 Homo sapiens
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.7.1.35 ATP + pyridoxal
-
 Homo sapiens ADP + pyridoxal 5'-phosphate
-
 ?
2.7.1.35 ATP + pyridoxamine
-
 Homo sapiens ADP + pyridoxamine 5'-phosphate
-
 ?